Parthenolide: suggested drug for COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the 2019 novel coronavirus (2019-nCoV) that causes acute respiratory distress syndrome (ARDS) which is the main reason for patients mortality. One of the effective treatments to reduce the effects of this virus is parthenolide (PN). Par...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
Sankt-Peterburg : NIIÈM imeni Pastera
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9315b89ca51547848e033744e355a25f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9315b89ca51547848e033744e355a25f |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9315b89ca51547848e033744e355a25f2021-11-22T07:09:55ZParthenolide: suggested drug for COVID-192220-76192313-739810.15789/2220-7619-PSD-1509https://doaj.org/article/9315b89ca51547848e033744e355a25f2020-11-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/1509https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the 2019 novel coronavirus (2019-nCoV) that causes acute respiratory distress syndrome (ARDS) which is the main reason for patients mortality. One of the effective treatments to reduce the effects of this virus is parthenolide (PN). Parthenolide is a sesquiterpene lactone found in medicinal plants. It can inhibit several pro-inflammatory signaling pathways, in particular the ATPase activity of NLRP3. Based on its ability to suppress inflammatory signal transduction and elevated level of serum IL-1β (a surrogate marker for NLRP3 activation) in COVID-19 patients, we suggest that PN could be potentiallyeffective for the treatment of COVID-19.M. NematiF. Danesh PouyaE. Roshani AslY. RamiSankt-Peterburg : NIIÈM imeni Pasteraarticleparthenolidecovid-19nf-kbInfectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 10, Iss 4, Pp 789-791 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU |
| topic |
parthenolide covid-19 nf-kb Infectious and parasitic diseases RC109-216 |
| spellingShingle |
parthenolide covid-19 nf-kb Infectious and parasitic diseases RC109-216 M. Nemati F. Danesh Pouya E. Roshani Asl Y. Rami Parthenolide: suggested drug for COVID-19 |
| description |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the 2019 novel coronavirus (2019-nCoV) that causes acute respiratory distress syndrome (ARDS) which is the main reason for patients mortality. One of the effective treatments to reduce the effects of this virus is parthenolide (PN). Parthenolide is a sesquiterpene lactone found in medicinal plants. It can inhibit several pro-inflammatory signaling pathways, in particular the ATPase activity of NLRP3. Based on its ability to suppress inflammatory signal transduction and elevated level of serum IL-1β (a surrogate marker for NLRP3 activation) in COVID-19 patients, we suggest that PN could be potentiallyeffective for the treatment of COVID-19. |
| format |
article |
| author |
M. Nemati F. Danesh Pouya E. Roshani Asl Y. Rami |
| author_facet |
M. Nemati F. Danesh Pouya E. Roshani Asl Y. Rami |
| author_sort |
M. Nemati |
| title |
Parthenolide: suggested drug for COVID-19 |
| title_short |
Parthenolide: suggested drug for COVID-19 |
| title_full |
Parthenolide: suggested drug for COVID-19 |
| title_fullStr |
Parthenolide: suggested drug for COVID-19 |
| title_full_unstemmed |
Parthenolide: suggested drug for COVID-19 |
| title_sort |
parthenolide: suggested drug for covid-19 |
| publisher |
Sankt-Peterburg : NIIÈM imeni Pastera |
| publishDate |
2020 |
| url |
https://doaj.org/article/9315b89ca51547848e033744e355a25f |
| work_keys_str_mv |
AT mnemati parthenolidesuggesteddrugforcovid19 AT fdaneshpouya parthenolidesuggesteddrugforcovid19 AT eroshaniasl parthenolidesuggesteddrugforcovid19 AT yrami parthenolidesuggesteddrugforcovid19 |
| _version_ |
1718417930871373824 |